Increased formation of oxidative DNA damage in human colonic mucosa with ulcerlative colitis

Nishibayashi, Hiroyuki; Kanayama, Seiji; Shinomura, Yasuhisa; Higashimoto, Yoshifumi; Miyagawa, Jun‐ichiro; Ariyoshi, Takashi; Miyazaki, Yoichi; Imanishi, K; Nakajima, Masaru; Takeuchi, T; Morimoto, K; Matsuzawa, Yūji

doi:10.1016/s0016-5085(98)82679-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IC 50 of these inhibitory reactions ranged from 0.05 to 2.0 m m for mesalazine, which correlates with concentrations found in the gut lumen of patients on mesalazine maintenance treatment. A clinical study performed in IBD patients treated with mesalazine for 1 month showed that the amount of hydroxylated DNA bases decreased significantly, supporting the concept that mesalazine may also have beneficial effects in clinical practice 30 . However, definitive conclusions from in vitro findings are not always completely correct, as effective concentrations maybe dependent on a variety of factors including, metabolic inactivation, i.e.…”

Section: Mechanisms Of Antiproliferative Action: Inhibition Of Reactimentioning

confidence: 99%

“…A clinical study performed in IBD patients treated with mesalazine for 1 month showed that the amount of hydroxylated DNA bases decreased significantly, supporting the concept that mesalazine may also have beneficial effects in clinical practice. 30 However, definitive conclusions from in vitro findings are not always completely correct, as effective concentrations maybe dependent on a variety of factors including, metabolic inactivation, i.e. the N-acetylation of free (active) mesalazine to N-acetyl-mesalazine (N-acetyl-aminosalicylic acid).…”

Section: Mechanisms Of Antiproliferative Action: Inhibition Of Reactimentioning

confidence: 99%

See 1 more Smart Citation

Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

Allgayer

2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary A series of epidemiological, experimental and preliminary clinical trials strongly suggest that mesalazine or 5‐aminosalicyclic acid (5‐ASA) may have antineoplastic and potentially prophylactic chemopreventive properties. It is assumed that mesalazine may have similar genetic and molecular targets as nonsteroidal anti‐inflammatory drugs (NSAIDs), which is further supported by its close similarity with aspirin, differing only in its structure by the presence of an amino group at position 5 of the benzene ring. The putative chemopreventive actions include the inhibition of inflammatory cascades and/or reactions involved in cell growth and proliferation, such as cyclo‐oxygenase (COX‐1 and COX‐2), which regulate cell proliferation through the formation of prostaglandins; lipoxygenase; nuclear factor κB (NFκB), responsible for the subsequent expression of pro‐inflammatory molecules; MAP kinases and Bcl‐2, as well as the activation of apoptotic processes, such as the stimulation of intestinal sphingomyelinase. The peroxisome‐proliferator‐activated receptor δ (PPARδ), which also regulates gene transcription, is thought to play a role in both inflammatory and non‐inflammatory driven carcinogenesis. This may be another significant target. It is hypothesized that 5‐ASAs may prevent the enhancing effect of prostaglandins on PPARδ binding to DNA by its COX inhibitory properties, decreasing proliferation of colorectal mucosal cells in non‐inflammatory bowel disease patients with sporadic polyps of the large bowel.

show abstract

Section: Mechanisms Of Antiproliferative Action: Inhibition Of Reactimentioning

confidence: 99%

Section: Mechanisms Of Antiproliferative Action: Inhibition Of Reactimentioning

confidence: 99%

Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

Allgayer

2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Increased formation of oxidative DNA damage in human colonic mucosa with ulcerlative colitis

Cited by 1 publication

References 0 publications

Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

Contact Info

Product

Resources

About